Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with myelofibrosis, previously treated with a Type I JAK2 inhibitor GlobeNewswire December 10, 2025 NEW YORK and CAMBRIDGE, Mass., […]